Showing 2,981 - 3,000 results of 21,342 for search '(( significant decrease decrease ) OR ( significant ((all decrease) OR (small decrease)) ))', query time: 0.50s Refine Results
  1. 2981

    Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

    Published 2025
    “…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”
  2. 2982

    Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

    Published 2025
    “…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”
  3. 2983

    Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

    Published 2025
    “…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”
  4. 2984
  5. 2985
  6. 2986
  7. 2987
  8. 2988
  9. 2989
  10. 2990
  11. 2991
  12. 2992
  13. 2993
  14. 2994
  15. 2995
  16. 2996
  17. 2997
  18. 2998
  19. 2999
  20. 3000